Takeda’s Alunbrig has beaten Pfizer’s Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer. More: Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC Source: News
read moreThe National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma. More: NICE backing for
read moreIn a clean sweep, the two top executives at Gilead Sciences will step down at the end of this year, setting the company up for a potentially entirely new approach. More: Gilead's top executives Milligan and Martin stepping down Source:
read moreRecipharm had a strong quarter as expansion added sales, contributing to a 21% jump. The Swedish CDMO reported sales of SEK 1.7 billion ($193 million) in a quarter that saw some key M&A deals that should contribute more revenue going
read moreForget the speculation you’ve heard over the past few days: GlaxoSmithKline is sticking with its three-unit structure, CEO Emma Walmsley says. And it’s rolling out a cost-cutting plan to make sure all three businesses have the funds they need. More:
read moreTakeda’s Alunbrig now sits in the back seat in ALK+ lung cancer, behind rivals from Pfizer, Novartis and Roche. But on Wednesday, the Japanese drugmaker racked up some new data that could help change that. More: Takeda's also-ran ALK drug Alunbrig
read more© 1994 - 2026 B.M. Pharmaceuticals